XML 33 R18.htm IDEA: XBRL DOCUMENT

Intangibles

12 Months Ended

Jun. 30, 2022

Text block [abstract]

Intangibles

Note 13. Intangibles

Non-current

assets


		Consolidated
		2022				2021
		A$’000				A$’000

Licensing agreement - Paxalisib			16,408				16,408
Less: Accumulated amortisation			(6,167	)			(5,082	)

			10,241				11,326

Licensing agreement - EVT-801			10,858				10,858
Less: Accumulated amortisation			(1,049	)			(181	)

			9,809				10,677

			20,050				22,003

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:


		EVT801 licensing agreement A$’000				Paxalisib licensing agreement A$’000				Total A$’000

Balance at 1 July 2020			—				12,410				12,410
Additions			10,858								10,858
Amortisation expense			(181	)			(1,084	)			(1,265	)

Balance at 30 June 2021			10,677				11,326				22,003

Amortisation expense			(869	)			(1,084	)			(1,953	)

Balance at 30 June 2022			9,808				10,242				20,050